
1. febs j. 2017 oct;284(19):3278-3301. doi: 10.1111/febs.14192. epub 2017 sep 11.

characterization plasma labile heme hemolytic conditions.

gouveia z(1), carlos ar(1), yuan x(2), aires-da-silva f(3)(4), stocker r(5)(6),
maghzal gj(5)(6), leal ss(7), gomes cm(7), todorovic s(7), iranzo o(7), ramos
s(1), santos ac(8)(9), hamza i(2), gonçalves j(8)(9), soares mp(1).

author information: 
(1)instituto gulbenkian da ciência, oeiras, portugal.
(2)department animal avian sciences department cell biology and
molecular genetics, university maryland, college park, md, usa.
(3)technophage s.a., lisboa, portugal.
(4)ciisa-faculdade de medicina veterinária, universidade de lisboa, portugal.
(5)vascular biology division, victor chang cardiac research institute,
darlinghurst, nsw, australia.
(6)school medical sciences, university new south wales, sydney, nsw,
australia.
(7)instituto de tecnologia química e biológica antónio xavier, universidade nova 
de lisboa, oeiras, portugal.
(8)imm, faculdade medicina, universidade de lisboa, portugal.
(9)cpm-uria, faculdade farmácia, universidade de lisboa, portugal.

extracellular hemoglobin, byproduct hemolysis, release prosthetic
heme groups upon oxidation. produces metabolically active heme is
exchangeable acceptor proteins, macromolecules low molecular weight
ligands, termed labile heme. accumulates plasma labile heme acts in
a pro-oxidant manner regulates cellular metabolism exerting
pro-inflammatory cytotoxic effects foster pathogenesis hemolytic 
diseases. here, developed characterized panel heme-specific single
domain antibodies (sdabs) together cellular-based heme reporter
assay, allow quantification characterization labile heme plasma
during hemolytic conditions. using approaches, demonstrate when
generated hemolytic conditions labile heme bound plasma molecules
with affinity higher 10-7 2-8% (~ 2-5 μm) total amount 
of heme detected plasma internalized bystander cells, termed here
bioavailable heme. acute, chronic, hemolysis associated transient
reduction plasma heme-binding capacity, is, ability plasma
molecules bind labile heme affinity higher 10-7 m. the
heme-specific sdabs neutralize pro-oxidant activity soluble heme vitro,
suggesting maybe used counter pathologic effects labile heme
during hemolytic conditions. finally, show heme-specific sdabs be
used visualize cellular heme. conclusion, describe panel of
heme-specific sdabs used approaches provide novel insights
to pathophysiology heme.

© 2017 authors. febs journal published john wiley & sons ltd behalf
of federation european biochemical societies.

doi: 10.1111/febs.14192 
pmcid: pmc5978748
pmid: 28783254  [indexed medline]

